There is definitely room for various outcomes. Too many unknowns at this point. What is the event rate of the placebo group? How does the additional low HDL requirement influence the actual event rate (estimates were based on EXAMINE trial without low HDL requirement)? As you asked, how much RRR is occurring in the combined statin group treated with apabetalone and is the apabetalone/rosuvastatin combo working better than the apabetalone/atorvastatin group? Is apabetalone even having an effect at all on reducing MACE? For these various reasons (and I likely missed some), there are opportunities for various outcomes and much uncertainty in the timing of the futility analysis. 

BearDownAZ